KMT2A and acute myeloid leukemia: The importance of aberrant transcriptional control is furthermore highlighted by fusions between KMT2A and lysine acetyltransferase 6A (KAT6A a.k.a. Monocytic leukemia zinc finger protein, MOZ, or MYST3) or 6B [KAT6B a.k.a. Moz-related factor (MORF) or MYST4] to the histone acetyl transferases EP300 or CREBBP in some rare cases of pediatric myelodysplastic syndromes (MDS) and AML (14–16).